Intelligent Bio Solutions partners with Syrma Johari Medtech for manufacturing; expects ~20ppt gross margin improvement

INTELLIGENT BIO SOLUTIONS INC.

Partnership with Syrma Johari Medtech to scale production of fingerprint drug screening reader; expects annual production cost savings >40%.
Company anticipates ~20 percentage point improvement in gross margin compared to previous arrangement.
Syrma Johari's manufacturing capacity ~4x current; supports planned U.S. market entry in 2026.
Syrma Johari operates 14 manufacturing locations, certified to ISO 13485, MDSAP, FDA, TUV SUD, GMP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.